Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.

about

Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.

Item

http://www.wikidata.org/entity/Q48531654

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.

@en

Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.

@nl

type

Item

label

Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.

@en

Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.

@nl

prefLabel

Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.

@en

Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.

@nl

P1476

Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery

@en

P2093

Chunquan Sheng

http://www.w3.org/2001/XMLSchema#string

Guoqiang Dong

http://www.w3.org/2001/XMLSchema#string

Wannian Zhang

http://www.w3.org/2001/XMLSchema#string

Ying Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Panobinostat for the treatment of multiple myeloma: the evidence to date

Epigenetic protein families: a new frontier for drug discovery

The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data.

New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations.

Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors

Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.

P304

34-38

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ACSMEDCHEMLETT.7B00414

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chao-Yu Miao

Wei Chen

P577

2017-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29348808

http://www.w3.org/2001/XMLSchema#string

P932

5767891

http://www.w3.org/2001/XMLSchema#string